Is Eli Lilly and Company (LLY) Strengthening Its Pain Management Strategy With New Biotech Acquisition?

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is one of the best weight loss drugs on this list.

TheFly reported on June 16 that LLY completed the acquisition of 4E Therapeutics, a neuroscience biotechnology company based in Austin, Texas. The acquired firm is focused on developing oral MNK inhibitor therapies for chronic pain and is advancing a pipeline aimed at modulating the MNK-eIF4E signaling pathway in peripheral sensory neurons. Through the transaction, LLY expands its presence in neuroscience and pain management research. Financial details of the acquisition were not disclosed by the companies.

Separately, on June 14, Eli Lilly and Company (NYSE:LLY) reported positive results from the Phase 3 BRUIN CLL-322 study evaluating Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial achieved its primary goal, showing that the addition of Jaypirca to a two-year venetoclax and rituximab treatment regimen lowered the risk of disease progression or death by 45% compared with venetoclax and rituximab alone. Data for overall survival, a major secondary endpoint, remain immature and will be assessed further in future analyses. The combination therapy also demonstrated an advantage in delaying the need for subsequent treatment, supporting its potential benefit in this patient population.

Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company and a major player in the weight-loss market, driven by strong demand for its obesity and diabetes treatments, including Zepbound and Mounjaro.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.